Synthesis, preclinical assessment, and first-in-human study of [18F]d4-FET for brain tumor imaging
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-024-06964-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Lu Hou und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharma…. Hauptthemen laut MEDLINE: Brain Neoplasms, Positron-Emission Tomography, Radiopharmaceuticals, Dideoxynucleosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Guangdong Science and Technology Planning Project, China, Guangzhou Science and Technology Program.
Abstract (Originalsprache)
PURPOSE: Tumor-to-background ratio (TBR) is a critical metric in oncologic PET imaging. This study aims to enhance the TBR of [18F]FET in brain tumor imaging by substituting deuterium ("D") for hydrogen ("H"), thereby improving the diagnostic sensitivity and accuracy. METHODS: [18F]d4-FET was synthesised by two automated radiochemistry modules. Biodistribution studies and imaging efficacy were evaluated in vivo and ex vivo in rodent models, while metabolic stability and radiation dosimetry were assessed in non-human primates. Additionally, preliminary imaging evaluations were carried out in five brain tumor patients: three glioma patients underwent imaging with both [18F]d4-FET and [18F]FET, and two patients with brain metastases were imaged using [18F]d4-FET and [18F]FDG. RESULTS: [18F]d4-FET demonstrated high radiochemical purity and yield. PET/MRI in rodent models demonstrated superior TBR for [18F]d4-FET compared to [18F]FET, and autoradiography showed tumor margins that correlated well with pathological extents. Studies in cynomolgus monkeys indicated comparable in vivo stability and effective dose with [18F]FET. In glioma patients, [18F]d4-FET showed enhanced TBR, while in patients with brain metastases, [18F]d4-FET displayed superior lesion delineation compared to [18F]FDG, especially in smaller metastatic sites. CONCLUSION: We successfully synthesized the novel PET radiotracer [18F]d4-FET, which retains the advantageous properties of [18F]FET while potentially enhancing TBR for glioma imaging. Preliminary studies indicate excellent stability, efficacy, and sensitivity of [18F]d4-FET, suggesting its potential in clinical evaluations of brain tumors. TRIAL REGISTRATION: ChiCTR2400081576, registration date: 2024-03-05, https://www.chictr.org.cn/bin/project/edit?pid=206162.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzho…
- Department of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
- Department of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518025, China.
- Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
- Department of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, GA, 30322, USA.
ORCID-Profile: Lu Wang
Förderung
- National Natural Science Foundation of China
- the Guangdong Science and Technology Planning Project, China
- Guangzhou Science and Technology Program
- the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University
Zitieren
APA
Hou, L., Chen, Z., Chen, F., Sheng, L., Ye, W., Dai, Y., Guo, X., Dong, C., Li, G., Liao, K., Li, Y., Ma, J., Wei, H., Ran, W., Shang, J., Ling, X., Patel, J. S., Liang, S. H., Xu, H., & Wang, L. (2025). Synthesis, preclinical assessment, and first-in-human study of [18F]d4-FET for brain tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06964-8
Vancouver
Hou L, Chen Z, Chen F, Sheng L, Ye W, Dai Y, et al. Synthesis, preclinical assessment, and first-in-human study of [18F]d4-FET for brain tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06964-8
BibTeX
@article{Hou2025,
author = {Hou, Lu and Chen, Zhiyong and Chen, Fanfan and Sheng, Lianghe and Ye, Weijian and Dai, Yingchu and Guo, Xiaoyu and Dong, Chenchen and Li, Guocong and Liao, Kai and Li, Yinlong and Ma, Jie and Wei, Huiyi and Ran, Wenqing and Shang, Jingjie and Ling, Xueying and Patel, Jimmy S and Liang, Steven H and Xu, Hao and Wang, Lu},
title = {Synthesis, preclinical assessment, and first-in-human study of [18F]d4-FET for brain tumor imaging},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-024-06964-8}
}
EUVIMED